(DIR) Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
(HTM) https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
(DIR) Return to: TYSABRI (natalizumab)
*****************************************************
#Post#: 1611--------------------------------------------------
Tysabri-related PML cases
By: agate Date: March 26, 2017, 5:51 pm
---------------------------------------------------------
New data reveal that as of March 6, 2017, there have been 714
confirmed Tysabri-related PML cases worldwide, with 711 of them
in persons with MS and 3 in persons with Crohn's disease.
As of February 28, 2017, overall PML incidence was 4.20 per 1000
patients (95% CI 3.89 to 4.52 per 1000 patients). 23% of the
patients have died; 77% of patients are alive with varying
levels of disability.
As of February 28, 2017, approximately 167,300 patients received
Tysabri in a post-marketing setting, worldwide.
#Post#: 1619--------------------------------------------------
711 cases of Tysabri-related PML in persons w/MS
By: ssalimi Date: April 2, 2017, 6:30 pm
---------------------------------------------------------
What was the source for this?
#Post#: 1623--------------------------------------------------
Re: 711 cases of Tysabri-related PML in persons w/MS
By: agate Date: April 2, 2017, 7:28 pm
---------------------------------------------------------
(HTM) https://chefarztfrau.de/?page_id=716
(HTM) https://chefarztfrau.de/?page_id=716
This is an unofficial source but apparently this guy (named
Alexander Otto) in Germany has access to the correct information
because he's been posting the data correctly for many years.
#Post#: 1734--------------------------------------------------
718 PML cases for PwMS as of 6/6/17, 24% have died
By: agate Date: June 26, 2017, 4:14 pm
---------------------------------------------------------
Updated, from the same source
:
[quote]As of June 06. 2017, there have been 731 (728 MS, 3 CD)
confirmed PML cases worldwide.
As of May 31, 2017, overall PML incidence: 4.21 per 1000
patients (95% CI 3.91 to 4.52 per 1000 patients). 24% of
patients have died; 76% of patients are alive with varying
levels of disability.
As of May 31, 2017, approximately 170,900 patients received
natalizumab in post-marketing setting worldwide.[/quote]
#Post#: 2555--------------------------------------------------
801 confirmed PML cases in MS patients on Tysabri (Dec. 2018)--F
ilgastrim for PML?
By: agate Date: June 19, 2019, 12:25 am
---------------------------------------------------------
The informal source that has been recording Tysabri-related PML
cases in MS patients hasn't been updated in over a year.
However, this article in Multiple Sclerosis News Today (June 28,
2019) reveals that as of 12/18, the total number of PML cases in
MS patients on Tysabri was 801. The article is about a possible
treatment for PML, filgrastim, and is entitled "Filgrastim
Likely Beneficial for Patients with Tysabri-Associated PML":
(HTM) https://multiplesclerosisnewstoday.com/filgastrim-beneficial-patients-tysabri-associated-pml/
#Post#: 4437--------------------------------------------------
Update on risk of Tysabri-linked PML presented at CMSC 2024
By: agate Date: May 29, 2024, 7:32 pm
---------------------------------------------------------
This information has been covered recently in other threads but
it's rather readably summarized here.
From Practical Neurology (May 28, 2024)--"Update on risk of PML
infection associated with Tysabri presented at CMSC 2024":
(HTM) https://bit.ly/4aWyf33
*****************************************************